Roche issues voluntary recall for Susvimo over manufacturing issue

It’s been almost a year since Roche’s blockbuster ocular implant, the wet age-related macular degeneration (AMD) drug Susvimo, was cleared for twice-annual administration as opposed to monthly injections. Now the company is putting a hold on it.